Ted Buchan & Co’s AbbVie ABBV Stock Holding History

Ted Buchan & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$399K	Hold	1,587	–	–	0.13%	72
2026 Q1	$345K	Hold	1,587	–	–	0.13%	68
2025 Q4	$363K	Sell	1,587 -13	-0.8%	-$2.96K	0.13%	71
2025 Q3	$370K	Buy	1,600 +13	+0.8%	+$2.65K	0.15%	67
2025 Q2	$295K	Hold	1,587	–	–	0.12%	83
2025 Q1	$333K	Hold	1,587	–	–	0.16%	71
2024 Q4	$282K	Hold	1,587	–	–	0.13%	78
2024 Q3	$313K	Hold	1,587	–	–	0.15%	74
2024 Q2	$272K	Hold	1,587	–	–	0.15%	75
2024 Q1	$289K	Hold	1,587	–	–	0.18%	76
2023 Q4	$246K	Sell	1,587 -45	-3%	-$6.56K	0.18%	74
2023 Q3	$243K	Hold	1,632	–	–	0.2%	68
2023 Q2	$220K	Hold	1,632	–	–	0.17%	77
2023 Q1	$260K	Buy	1,632 +80	+5%	+$12.2K	0.22%	65
2022 Q4	$251K	Buy	+1,552	New	+$238K	0.23%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ted Buchan & Co's ABBV Position: Q2 2026 in Review

Ted Buchan & Co held its AbbVie (ABBV) position steady in Q2 2026 at 1,587 shares worth $399K. The position accounts for 0.13% of the portfolio, ranked #72.

Ted Buchan & Co first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Ted Buchan & Co held 1,587 shares of AbbVie worth $399K as of Q2 2026.
Ted Buchan & Co left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.13% of Ted Buchan & Co's portfolio in Q2 2026, its #72 holding.
Ted Buchan & Co first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ted Buchan & Co's 13F filing for Q2 2026, filed 23 Jul 2026.